Positive PhIII data from Gilead's elvitegravir stands up at two years
12 December 2011
Nancy Faigen
Please Login to read the full article.
12 December 2011
Nancy Faigen
nancy.faigen@informausa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- Gilead's 2nd positive Phase III sets up early FDA submission for Quad
- Merck's raltegravir combination beats efavirenz combo in treatment-naive HIV
- Gilead's HIV Quad meets primary endpoint, but not investors' expectations
- Tibotec, Gilead in two potential deals for HIV combinations
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
